Integra LifeSciences Holdings Corporation

Equities

IART

US4579852082

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
32.06 USD -2.26% Intraday chart for Integra LifeSciences Holdings Corporation -6.91% -26.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
North American Morning Briefing : Focus Turns to -2- DJ
Citigroup Upgrades Integra LifeSciences to Neutral From Sell With $38 Price Target MT
Citigroup Upgrades Integra LifeSciences to Neutral From Sell, Price Target is $38 MT
Integra LifeSciences Completes Acquisition of Acclarent MT
Integra LifeSciences Holdings Corporation acquired 100% stake in Acclarent, Inc. from Ethicon US, LLC for $280 million. CI
Integra Lifesciences Launches Micromatrix Flex to Provide Convenient Access to Hard-To-Reach Areas in Complex Cases CI
Integra Lifesciences Holdings Insider Sold Shares Worth $305,492, According to a Recent SEC Filing MT
Truist Securities Cuts Price Target on Integra LifeSciences Holdings to $41 From $46, Maintains Hold Rating MT
Tranche Update on Integra LifeSciences Holdings Corporation's Equity Buyback Plan announced on July 27, 2023. CI
Integra LifeSciences Shares Drop Following Q4 Results MT
Integra LifeSciences Seeks Acquisitions CI
Transcript : Integra LifeSciences Holdings Corporation, Q4 2023 Earnings Call, Feb 28, 2024
Integra LifeSciences' Q4 Adjusted Earnings, Revenue Decline MT
Integra LifeSciences Holdings Corporation Announces the Retirement of Jan De Witte as Chief Executive Officer CI
Integra LifeSciences Holdings Corporation Announces Board Changes CI
Integra Lifesciences Holdings Corporation Provides Earnings Guidance for the First Quarter and for the Full Year 2024 CI
Integra LifeSciences Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Posts Q4 Revenue $397M, vs. Street Est of $399.2M MT
Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Reports Q4 EPS $0.89, vs. Street Est of $0.90 MT
Integra LifeSciences Holdings Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Integra LifeSciences Holdings Corporation Appoints Jeffrey Alan Graves on the Compensation Committee of the Board CI
Transcript : Integra LifeSciences Holdings Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM
Truist Securities Adjusts Price Target on Integra LifeSciences to $46 From $44, Maintains Hold Rating MT
Truist Adjusts Integra LifeSciences Holdings' Price Target to $44 From $39, Keeps Hold Rating MT
Integra LifeSciences Agrees to Buy Acclarent for $275 million at Deal Closing MT
Chart Integra LifeSciences Holdings Corporation
More charts
Integra LifeSciences Holdings Corporation is a global medical technology company. The Company manufactures and sells medical technologies and products in two segments: Codman Specialty Surgical (CSS) and Tissue Technologies (TT). The CSS segment consists of technologies and instrumentation used for a range of specialties, such as neurosurgery, neurocritical care and otolaryngology. The CSS business consists of a portfolio of brands, such as Codman, DuraGen, DuraSeal, CUSA, Mayfield, Bactiseal, and Certas Plus, which are used for the management of multiple disease states, including brain tumors, traumatic brain injury, hydrocephalus and other neurological conditions. The Company provides instruments that are used in precision, specialty and general surgical procedures. The TT segment is focused on three main areas: complex wound surgery, surgical reconstruction and peripheral nerve repair. The TT segment offers skin and wound repair, bone grafts, and nerve and tendon repair products.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
32.06 USD
Average target price
44.8 USD
Spread / Average Target
+39.74%
Consensus
  1. Stock Market
  2. Equities
  3. IART Stock
  4. News Integra LifeSciences Holdings Corporation
  5. Integra LifeSciences : Earnings Flash (IART) INTEGRA LIFESCIENCES HOLDINGS CORPORATION Posts Q4 Revenue $388.6M, vs. Street Est of $386M